Radioimmunotherapy

Radioimmunotherapy (RIT) represents a sophisticated form of cancer treatment that blends the targeting capabilities of immunotherapy with the cell-killing power of radiation therapy. This innovative treatment employs radioactive isotopes attached to monoclonal antibodies—proteins engineered to bind specifically to cancer cells. The concept harnesses the antibody’s ability to target tumour cells, delivering lethal radiation directly to the malignant cells while minimising exposure to healthy tissue.

The mechanism of RIT is rooted in its dual-action approach. Monoclonal antibodies are designed to recognise and attach to specific antigens present on the surface of cancer cells. Once these antibodies bind to the cancer cells, the radioactive isotopes deliver focused radiation, inducing DNA damage and cell death within the tumour. This targeted approach allows higher radiation doses to be used compared to conventional radiotherapy, where the risk of damaging healthy tissue often limits the dosage.

Radioimmunotherapy has shown particular promise in the treatment of certain types of blood cancers, such as non-Hodgkin lymphoma (NHL). Two of the well-known RIT drugs approved for clinical use are Ibritumomab Tiuxetan (Zevalin) and Tositumomab (Bexxar), both of which have demonstrated efficacy in treating NHL that have not responded to other treatments. These treatments involve pre-dosing with an unlabelled antibody to clear out excess B-cells and improve targeting, followed by administration of the radiolabelled antibody.

Even though it has advantages, RIT is not devoid of challenges. The precision of the treatment depends heavily on the expression of antigens on cancer cells, which can vary widely among patients and even within a tumour. Moreover, the complexity of developing and producing radiolabelled antibodies can make RIT more expensive and less accessible than more conventional treatments. Additionally, patients undergoing RIT can experience side effects similar to those of other forms of radiation, such as fatigue, nausea, and more severe complications like cytopenias, where the blood has lower counts of cells, which increases the risk of infection and bleeding.

Ongoing research and development are essential to overcoming these hurdles. Advances in imaging and radiolabelling techniques may enhance the delivery and efficacy of RIT. Furthermore, combining RIT with other forms of cancer therapy, such as chemotherapy or newer forms of immunotherapy, might provide synergistic effects that could lead to better outcomes for patients.

In conclusion, radioimmunotherapy represents a significant advance in the fight against cancer. It offers a potent, targeted option that can be particularly beneficial for patients with certain types of resistant or recurrent cancers. As research progresses, it holds the promise of more refined and broadly applicable cancer treatments, heralding a new era in oncological therapy.

home » Radioimmunotherapy

Scroll to Top